By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Doritos and Cheetos dial back the bright orange in new versions without artificial ingredients - 2Figure out How to Adjust Work, Life, and an Internet based Degree
- 3Big majority in Germany call Berlin's efforts on gas prices too weak
- 4Factbox-Artemis II crew includes first woman, Black astronaut and Canadian ever flown to moon
- 521 Things You Ought to Never Share with Your Childless Companion
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- Find the Historical backdrop of the Modern Unrest: Changing Society and Innovation
- Doctors seek to understand why quitting antidepressants causes withdrawal for some
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- 10 Moving Design Frill for Summer 2023
- Manual for 10 Scrumptious Specialty Mixed drinks
- Inn The executives: A Remunerating Profession Decision for Energetic People
- Am I a Summer, or is this a scam? What I learned from color analysis.
- Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts
